Bifogade filer
PDF
Beskrivning
| Land | Danmark |
|---|---|
| Lista | First North Stockholm |
| Sektor | Hälsovård |
| Industri | Bioteknik |
THIS PRESS RELEASE IS NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, WITHIN OR TO THE UNITED STATES, AUSTRALIA, CANADA, HONG KONG, JAPAN, NEW ZEALAND, SINGAPORE, SOUTH AFRICA, SOUTH KOREA, SWITZERLAND OR IN ANY OTHER JURISDICTION WHERE SUCH RELEASE, DISTRIBUTION OR PUBLICATION WOULD BE UNLAWFUL OR WOULD REQUIRE REGISTRATION OR ANY OTHER MEASURES IN ACCORDANCE WITH APPLICABLE LAW.
Hørsholm, Denmark, September 29, 2020 - the Extraordinary General Meeting ("EGM") of ExpreS2ion Biotech Holding AB (publ) ("ExpreS2ion" or the "Company") resolved on September 23, 2020 to carry out a share issue with preferential rights for the Company's existing shareholders including warrants (the "Offering"). Upon full subscription in the Offering, the Company will receive approx. SEK 131 million. If the warrants are exercised in full, the Company will additionally receive up to approx. SEK 85 million before deduction of costs related to the Offering. The board of directors of ExpreS2ion has in connection with the Offering, and prior to the subscription period that commences on 5 October 2020, prepared a prospectus which today has been approved by the Swedish Financial Supervisory Authority (Sw. Finansinspektionen) (the "SFSA").
Publication of the prospectus
For complete information about the Offering, please refer to the prospectus that has been prepared by the Company and that today has been approved by the SFSA. The prospectus is available on ExpreS[2]ion's website (www.expres2ionbio.com) and Arctic Securities website (www.arctic.com/secse) and will also be available on the SFSA's website (https://fi.se/sv/vara-register/prospektregistret/). The prospectus will be passported to Denmark and thus also available for Danish investors.
The prospectus is prepared as an EU-Growth prospectus in accordance with article 15 in the Regulation (EU) 2017/1129 (the "Prospectus Regulation"). The prospectus has been approved by the SFSA, which is the Swedish competent authority in accordance with the Prospectus Regulation, in accordance with article 20 in the Prospectus Regulation. The SFSA only approves the prospectus as meeting the standards of completeness, comprehensibility and consistency imposed by the Prospectus Regulation. The approval should not be considered as an endorsement of ExpreS[2]ion or as an endorsement of the quality of the shares that are the subject of the prospectus and does not indicate that the SFSA guarantees that the facts in the prospectus are correct or complete. Investors should make their own assessment as to the suitability of investing in the Offering.
Application forms will be available on the Company's and Arctic Securtities website respectively.
Timetable for the Offering
Last day of trading in shares September 29, 2020
including right to receive Unit
rights
First day of trading in shares September 30, 2020
excluding right to receive Unit
rights
Prospectus published (Denmark) Around September 30, 2020
Record date for participation in October 1, 2020
the Offering
Subscription period October 5 - October 19, 2020
Trading in Unit rights October 5 - October 15, 2020
Trading in BTUs (Paid subscribed October 5, 2020 - until the Offering is
Units) registered with the Swedish Companies
Registration Office (Sw. Bolagsverket)
Announcement of final outcome in Around October 26, 2020
the Offering
Advisors
Arctic Securities AS, filial Sverige and Translution Capital ApS act as financial advisors to the Company in connection with the Offering. Arctic Securities is the Company's issuing agent whereas Baker Mckenzie is the Company's legal advisor in connection with the Offering.
Certified Adviser
Svensk Kapitalmarknadsgranskning AB
Telefon: +46 11 32 30 732
E-post: ca@skmg.se